BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The field of Hippo Pathway targeted drugs is seeing a surge of
  activity\, with new clinical data being generated everyday and novel com
 binations being tested. The 3rd Hippo Pathway Targeted Drug Development S
 ummit has been built alongside industry experts from the likes of Vivace 
 Therapeutics\, Orion Pharma\, Insilico Medicine and more to return as the
  premier event for Hippo industry leaders focusing on developing innovati
 ve\, safe\, and effective therapies in oncology\, fibrosis\, and beyond.\
 n\nJoin over 20 global Hippo experts as we advance YAP\, TAZ\, and TEAD m
 odulators towards clinical success - right from the comfort of your scree
 n! This is your virtual hub to meet 80+ Hippo experts from across the glo
 be gathering for data-led presentations\, deep-diving panels\, and intera
 ctive roundtables to advance the Hippo industry forward.\n\nURLs:Tickets:
  https://go.evvnt.com/2628622-2?pid=185Brochure: https://go.evvnt.com/262
 8622-3?pid=185\n\nTime: 8:00 AM - 4:40 PM\n\nSpeakers: John Lamar\, Assoc
 iate Professor\, Albany Medical College\, Shirley Guo\, Director of Biolo
 gy\, BridGene Biosciences\, Jidong Zhu\, Co-Founder and Chief Executive O
 fficer\, Etern Therapeutics\, Michelle Chen\, Chief Business Officer\, In
 silico Medicine\, Arianna Sabo\, Head of Research and Discovery\, QUANTRO
  Therapeutics GmbH\, Srinivas Vinod Saladi\, Assistant Professor of Cell 
 and Cancer Biology\, University of Toledo\, College of Medicine and Life 
 Sciences\, Jeff Holden\, Head of Structural Biology\, Vilya Therapeutics\
 , David Lagares\, Chief Executive Officer and Founder\, Zenon Biotech\, W
 anjin Hong\, Professor and Chief Business Development Officer\, Biomedica
 l Research Council (BMRC)\, A*STAR\, Ajaybabu Pobbati\, Assistant Profess
 or\, Cleveland Clinic\, Alissa Guarnaccia\, Postdoctoral Researcher\, Gen
 entech\, Carsten Hansen\, Reader\, Institute for Regeneration and Repair\
 , University of Edinburgh\, Shengli Dong\, Executive Director\, Biology\,
  Tyk Medicines\, Alessia Mira\, Senior Scientist\, Molecular Biotechnolog
 y Center\, University of Torino\, Melanie Frigault\, Consultant\, Transla
 tional Medicine\, Vincerx Pharma\, Federico Mauri\, Principal Scientist\,
  Boehringer Ingelheim\, Zhi Liang Chu\, Founder and Chief Executive Offic
 er\, Crossignal Therapeutics\, Seung Hyun Jung\, Team Leader\, Targeted O
 ncology Research Team\, Hanmi Pharma \, Satu Juhila\, Project Leader\, Ea
 rly Clinical Development Oncology\, Orion Pharma\, Chenglong Li\, Nichola
 s Bodor Professor in Drug Discovery\, University of Florida\, Kari Kurppa
 \, Principal Investigator\, University of Turku\, Neelesh Sharma\, Chief 
 Medical Officer\, Vivace Therapeutics\n
DTEND:20241121T164000
DTSTAMP:20260512T231942Z
DTSTART:20241120T080000
LOCATION:Online\, Virtual\, Digital\, Live\, Webinar\,
SEQUENCE:0
SUMMARY:The field of Hippo Pathway targeted drugs is seeing a surge of act
 ivity\, with new clinical data being generated everyday and novel combina
 tions bei...
UID:1e11d914-fac5-4548-b799-c8b59f154617
END:VEVENT
END:VCALENDAR